MTOR and acute myeloid leukemia: PI3K-AKT-mTOR pathway was constitutively activated in 60% of AML patients, and the over-activation of PI3K-AKT-mTOR was associated with poor survival of AML patients (Min et al., 2003; Kornblau et al., 2009; Chen et al., 2010; Nepstad et al., 2018; Nepstad et al., 2019).